Synthetic lipopeptide vaccines with B-, T-helper- and T-killer cell response and built in adjuvanticity

The N-terminus of bacterial lipoprotein tripalmitoyl-S-glyceryl-cysteinyl-serine (P₃CS) has been synthesized for the first time in our laboratory.  P₃CS and  water –soluble lipopeptides such as P₃CSK₄  proved to be powerful immunoadjuvants activating Toll-like receptors TLR 1,2. The conjugation of P₃CS with species- and allele-specific B-, T-helper- and CTL-epitopes allowed us to prepare chemically defined, complete minimal lipopeptide vaccines with molecular masses below 5000. The synthetic lipopeptides allowed for the first time the in vivo priming of cytotoxic T-lymphocytes and antibody formation.

Lipopeptides are available at EMC microcollections.

Synthetic adjuvant Pam₃Cys-Ser-(Lys)₄

G. Jung, K.-H. Wiesmüller, G. Becker, H.-J. Bühring and W.G. Bessler (1985). Increased Production of Specific Antibodies by presentation of the Antigen Determinants with Covalently Coupled Lipopeptide  Mitogens, Angew. Chem. 97, 883-885; Angew. Chem. Int. Ed. Eng. 24, 872-873.

K.  Deres, H.-J. Schild, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee (1989). In vivo Priming of Virus Specific Cytotoxic T Lymphocyte with Synthetic Lipopeptide Vaccine, Nature 342,561-564.

K.-H. Wiesmüller, G. Jung, and G. Hess (1989). Novel Low-Molecular-Weight Synthetic Vaccine against Foot-and Mouth Disease Containing a Potent B-Cell and Macrophage Activator, Vaccine 7, 29-33.

K.-H. Wiesmüller, G. Jung, D.Gillessen, C. Loffl, W. G. Bessler, and T. Böltz (1991).
The Antibody Response in BALB/c Mice to the Plasmodium falciparum circumsporozoite Repetitive Epitope Covalently Coupled to Lipopeptide Analogues, Immunology 72, 109-113.

H. Schild, K. Deres, K.-H. Wiesmüller, G. Jung, and H.-G. Rammensee (1991).
Efficiency of Peptides and Lipopeptides for in vivo Priming of Virus Specific Cytotoxic T-Cells, Eur. J. Immunol. 21, 2649-2654.

J.W. Metzger, W. Beck, and G. Jung (1992). Ion Spray Mass Spectrometry of Lipopeptide Vaccines, Angew. Chem. 104, 235-237; Angew. Chem. Inf. Ed. Eng. 31, 226-228.

J.W.Metzger, W.H.Sawyer, B.Wille, L.Biesert, W.G.BessIer, and G.Jung (1993).
Interaction of Immunologically Active Lipopeptides with Membranes, Biochim.
Biophys. Acta 1149, 29-39.

E. Borges, K.-H. Wiesmüller, G. Jung, and P. WaIden (1994). Efficacy of Synthetic Lipopeptide Vaccines in the Induction of Cytotoxic T Lymphocytes: Comparison of the Costimulating Support Provided by Helper T cells and Lipoamino Acid, J. Immunol. Methods 173, 253-263.

K.-H. Wiesmüller, B. Fleckenstein, and G. Jung (2001). Peptide Vaccines and Peptide Libraries (Review), Biol. Chem. 382, 571-579.

R. Spohn, U. Buwitt-Beckmann, R. Brock, G. Jung, A.J. Ulmer, and K.-H. Wiesmüller (2004). Synthetic Lipopeptide Adjuvants and Toll-like Receptor 2 – Structure-Activity Relationships, Vaccine 22, 2494-2499.

U. Buwitt-Beckmann, H. Heine, K.-H. Wiesmüller, G. Jung, R. Brock, S. Akira, and   A.J. Ulmer (2006). TLR1- and TLR6-Independent Recognition of Bacterial Lipopeptides, J. Biol. Chem. 281, 9049-9057.

T. Seyberth, S. Voss, R. Brock, K.-H. Wiesmüller, and G. Jung (2006). Lipolanthionine Peptides Act as Inhibitors of TLR2 Mediated IL-8 Secretion. Synthesis and Structure-Activity Relationships,  J. Med. Chem. 49, 1754-1765.

A.B. Schromm, J. Howe, A.J. Ulmer, K.-H. Wiesmüller, T. Seyberth, G. Jung, M. Rössle, M.H.J. Koch, T. Gutsmann, and K. Brandenburg (2007). Physicochemical and Biological Analysis of Synthetic Bacterial Lipopeptides: Validity of the Concept of ‘’Endotoxic Conformation’’, J. Biol. Chem. 282, 11030-11037.